Myocardial ischemic post-conditioning protects the lung against myocardial ischemia/reperfusion-induced damage by activating GSK-3β

Acta Cir Bras. 2017 May;32(5):376-387. doi: 10.1590/s0102-865020170050000007.

Abstract

Purpose:: To investigate whether modulating GSK-3β could attenuate myocardial ischemia reperfusion injury (MIRI) induced acute lung injury (ALI) and analyze the underlying mechanism.

Methods:: Male SD rats were subjected to MIRI with or without myocardial ischemic post-conditioning in the presence or absence of GSK-3β inhibitor. GSK-3β inhibitor was injected peritoneally 10min before MIRI. Lung W/D weight ratio, MPO, PMNs, histopathological changes, TUNEL, Bax, Bcl-2, IL-6, IL-8, IL-10, GSK-3β, and caspase-3 were evaluated in the lung tissues of all rats.

Results:: After MIRI, lung injury was significantly increased manifested as significant morphological changes and increased leukocytes in the interstitial capillaries, Lung W/D ratio, MPO, and PMN in BALF, which was associated with enhanced inflammation evidenced by increased expressions of IL-6, IL-8 and reduced expression of IL-10. MIRI significantly increased cell apoptosis in the lung as increased levels of apoptotosis, Bax, cleaved caspase-3, and reduced expression of Bcl-2 was observed, which was concomitant with reduced p-GSK-3β. All these changes were reversed/prevented by ischemic post-conditioning, while these beneficial effects of ischemic post-conditioning were abolished by GSK-3β inhibition.

Conclusion:: Myocardial ischemia reperfusion injury induces acute lung injury by induction of inflammation and cell apoptosis. Ischemic post-conditioning protects the lung from ALI following MIRI by increasing p-GSK-3β.

MeSH terms

  • Acute Lung Injury / enzymology
  • Acute Lung Injury / prevention & control*
  • Animals
  • Apoptosis / drug effects
  • Caspase 3 / metabolism
  • Down-Regulation
  • Enzyme Activation
  • Glycogen Synthase Kinase 3 beta / antagonists & inhibitors
  • Glycogen Synthase Kinase 3 beta / metabolism*
  • Glycogen Synthase Kinase 3 beta / pharmacology
  • In Situ Nick-End Labeling
  • Inflammation / metabolism
  • Interleukins / metabolism
  • Ischemic Postconditioning / methods*
  • Male
  • Models, Animal
  • Myocardial Infarction / pathology
  • Myocardial Reperfusion Injury / prevention & control*
  • Neutrophils / enzymology
  • Peroxidase / metabolism
  • Protective Agents / metabolism*
  • Protective Agents / pharmacology
  • Proto-Oncogene Proteins c-bcl-2 / metabolism
  • Random Allocation
  • Rats, Sprague-Dawley
  • bcl-2-Associated X Protein / metabolism

Substances

  • Interleukins
  • Protective Agents
  • Proto-Oncogene Proteins c-bcl-2
  • bcl-2-Associated X Protein
  • Peroxidase
  • Glycogen Synthase Kinase 3 beta
  • Caspase 3